Literature DB >> 9117807

Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.

Z Najari1, W J Rusho.   

Abstract

The Y-site compatibility of medications routinely used in bone marrow transplant patients was studied. Two methods were used to evaluate the compatibility of pairs of various i.v. drugs and nutrient fluids. In the first, the drugs were combined in a 1:1 ratio in test tubes, which were visually evaluated immediately and at 1, 4, and 24 hours under normal light and against a white background. The second method involved simulated infusion through a Y-site and a membrane filter. Filter disks were examined under 51 x magnification for precipitates. "Administration" time ranged from one minute to five hours. Most of the combinations were compatible. Exceptions (incompatibilities or inconclusive findings) were amikacin plus a total parenteral nutrient (TPN) admixture; cyclosporine plus dopamine hydrochloride, magnesium sulfate, ondansetron, a parenteral nutrient solution, the TPN admixture, or the TPN admixture with phytonadione; and heparin sodium in either 5% dextrose injection or 0.9% sodium chloride injection plus the TPN admixture or vancomycin. The two study methods were in agreement for all drug combinations except those involving cyclosporine. Cyclosporine in 0.9% sodium chloride injection yielded many fine particles on the filter disk. The combination of cyclosporine with other drugs did not appear to increase the number of particles on the disk, but the results must still be considered inconclusive. Two methods used to determine the compatibility of bone marrow transplant agents when mixed in a Y injection site yielded the same results, except for combinations involving cyclosporine. Most of the combinations were compatible.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9117807     DOI: 10.1093/ajhp/54.2.181

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  4 in total

1.  Vancomycin-induced red man syndrome in pediatric oncology: still an issue?

Authors:  Tiene Bauters; Barbara Claus; Petra Schelstraete; Hugo Robays; Yves Benoit; Catharina Dhooge
Journal:  Int J Clin Pharm       Date:  2011-12-13

2.  Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story?

Authors:  Wesley D Kufel; Christopher D Miller; Paul R Johnson; Kaleigh Reid; James J Zahra; Robert W Seabury
Journal:  Hosp Pharm       Date:  2017-02

3.  Transplacental passage of vancomycin in the ex vivo human perfusion model.

Authors:  Michael D Hnat; Julie Gainer; Roger E Bawdon; George D Wendel
Journal:  Infect Dis Obstet Gynecol       Date:  2004-06

4.  Stability of vancomycin hydrochloride employed in antimicrobial seal solutions of central intravenous catheters.

Authors:  Daniele Porto Barros; Priscilla Sete de Carvalho Onofre; Fernando Luiz Affonso Fonseca; Paulo César Pires Rosa; Mavilde da Luz Gonçalves Pedreira; Maria Angélica Sorgini Peterlini
Journal:  Rev Lat Am Enfermagem       Date:  2022
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.